scholarly article | Q13442814 |
P356 | DOI | 10.1002/BIMJ.201100062 |
P932 | PMC publication ID | 3715690 |
P698 | PubMed publication ID | 22095849 |
P894 | zbMATH Open document ID | 1239.62130 |
P50 | author | Donna Ankerst | Q58241772 |
Alan W Partin | Q62089936 | ||
P2093 | author name string | Yuanyuan Liang | |
Ian M Thompson | |||
Daniel W Chan | |||
Ziding Feng | |||
Jacob Kagan | |||
Robin J Leach | |||
Martin G Sanda | |||
John T Wei | |||
Lori Sokoll | |||
Tim Koniarski | |||
P2860 | cites work | American Cancer Society guideline for the early detection of prostate cancer: update 2010 | Q28274848 |
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond | Q29614697 | ||
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach | Q29614698 | ||
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines | Q29619614 | ||
Multiple imputation of discrete and continuous data by fully conditional specification | Q31118138 | ||
Missing covariate data in medical research: to impute is better than to ignore | Q33546257 | ||
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness | Q33839248 | ||
Phases of biomarker development for early detection of cancer | Q34311577 | ||
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter | Q34323096 | ||
Estimating the diagnostic likelihood ratio of a continuous marker | Q34425390 | ||
The influence of finasteride on the development of prostate cancer | Q34534815 | ||
Decision curve analysis: a novel method for evaluating prediction models | Q34581068 | ||
Predicting prostate cancer risk through incorporation of prostate cancer gene 3. | Q34809531 | ||
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone | Q35924515 | ||
Assessing the performance of prediction models: a framework for traditional and novel measures | Q36617895 | ||
Estimating the capacity for improvement in risk prediction with a marker | Q37090852 | ||
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers | Q37252155 | ||
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower | Q39722492 | ||
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial | Q39752227 | ||
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population | Q39778617 | ||
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection | Q39904254 | ||
Projecting individualized absolute invasive breast cancer risk in African American women | Q40149673 | ||
A review of goodness of fit statistics for use in the development of logistic regression models | Q40338804 | ||
Decision curve analysis: a discussion | Q41976258 | ||
A new logistic regression approach for the evaluation of diagnostic test results | Q43760998 | ||
The need for reorientation toward cost-effective prediction: comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10 | Q46355737 | ||
Bayesian inference for finite mixtures of univariate and multivariate skew-normal and skew-t distributions. | Q46390591 | ||
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually | Q69396132 | ||
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy | Q82228594 | ||
P433 | issue | 1 | |
P921 | main subject | prostate cancer | Q181257 |
P6104 | maintained by WikiProject | WikiProject Mathematics | Q8487137 |
P304 | page(s) | 127-142 | |
P577 | publication date | 2011-11-17 | |
P1433 | published in | Biometrical Journal | Q15720842 |
P1476 | title | Updating risk prediction tools: a case study in prostate cancer | |
P478 | volume | 54 |
Q39108831 | Comparison of approaches for incorporating new information into existing risk prediction models |
Q38017952 | Fracture risk assessment: state of the art, methodologically unsound, or poorly reported? |
Q35940811 | Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators |
Q36146528 | Improving prediction models with new markers: a comparison of updating strategies |
Q50107743 | Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator |
Q37279076 | Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator |
Q58796826 | Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer |
Q38881882 | Key steps and common pitfalls in developing and validating risk models. |
Q36093723 | Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator |
Q33672510 | Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer |
Q35996067 | Prostate cancer risk prediction in a urology clinic in Mexico |
Q91899181 | Quantifying the incremental value of deep learning: Application to lung nodule detection |
Q38068114 | Risk stratification in prostate cancer screening. |
Q35013380 | Tailoring the implementation of new biomarkers based on their added predictive value in subgroups of individuals |
Q36185925 | The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting |
Q38211603 | The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used? |
Q40037072 | The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study |
Q59575001 | Translational Risk Models |